ERYTECH to Present at the JMP Securities Hematology Summit
LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced todaythat CEO, Gil Beyen, will present at the JMP Securities Hematology Summit Tuesday December 15th at 1:30pm EST /06:30pm GMT /7:30pm CET. The format will be a “fireside chat” discussion hosted by JMP Securities' Reni Benjamin.
The event will be held virtually, with all corporate and institutional participants joining remotely.
About ERYTECH and eryaspase
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia was recently completed in the Nordic countries of Europe. Eryaspase is not approved in any country.
ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.erytech.com
This press release contains forward-looking statements including but not limited to statements with respect to the clinical development plans of eryaspase; the potential indications for and benefits of eryaspase; statements relating to the TRYbeCA-1 clinical trial, including the timeline for patient enrollment as well as expected timing of the availability of results and interim superiority analysis; potential impacts on the Company’s clinical trials, including TRYbeCA-1 clinical trial, due to the coronavirus (COVID-19) pandemic such as delays in regulatory review, manufacturing and supply chain interruptions; and the overall impact of the COVID-19 pandemic on the global healthcare system as well as the Company’s business, financial condition and results of operations. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results and timeline may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2019 Document d’Enregistrement Universel filed with the AMF on March 18, 2020 and in the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2020 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. In addition, the COVID-19 pandemic and the associated containment efforts have had a serious adverse impact on the economy, the severity and duration of which are uncertain. Government stabilization efforts will only partially mitigate the consequences. The extent and duration of the impact on the Company’s business and operations is highly uncertain, and that impact includes effects on its clinical trial operations and supply chain. Factors that will influence the impact on the Company’s business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. The pandemic could have a material adverse impact on the Company’s business, operations and financial results for an extended period of time.
CFO & COO
|LifeSci Advisors, LLC|
Corey Davis, Ph.D.
Mathilde Bohin /
+33 4 78 74 44 38
+1 (212) 915 - 2577
+33 1 44 71 94 94
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Nykredit Bank A/S är nytt emissionsinstitut under Klöverns icke-säkerställda MTN-program15.1.2021 13:30:00 CET | Pressemelding
Nykredit Bank A/S har genom ett avtal daterat den 14 januari 2021 tillträtt som emissionsinstitut under Klövern AB (publ)s icke-säkerställda MTN-program (”MTN-programmet”) i enlighet med de allmänna villkoren för MTN-programmet ursprungligen daterade den 4 februari 2020 och såsom ändrade den 6 oktober 2020. Övriga emissionsinstitut under MTN-programmet är Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank Abp och Swedbank AB (publ). Mer information om MTN-programmet finns på Klöverns webbplats (www.klovern.se). Klövern AB (publ) För ytterligare information, vänligen kontakta: Jens Andersson, Finanschef, 076-855 67 02, email@example.com Rutger Arnhult, VD, 070-458 24 70, firstname.lastname@example.org Lars Norrby, IR, 076-777 38 00, email@example.com Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterat på Nasdaq Stockholm. Ytterligare information finns på www.klovern.se. Klövern AB (publ), Bredgränd 4,
Nykredit Bank A/S is new dealer under Klövern’s unsecured MTN Program15.1.2021 13:30:00 CET | Press release
Nykredit Bank A/S has through an agreement dated on 14 January 2021 acceded to Klövern AB (publ)’s unsecured MTN program (the ”MTN Program”) as dealer in accordance with the general terms and conditions of the MTN Program originally dated on 4 February 2020 and as amended on 6 October 2020. The other dealers under the MTN Program are Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank Abp and Swedbank AB (publ). Further information about the MTN Program can be found on Klövern’s website (www.klovern.se). Klövern AB (publ) For additional information, please contact: Jens Andersson, Head of Finance, +46 (0)76-855 67 02, firstname.lastname@example.org Rutger Arnhult, CEO, +46 (0)70-458 24 70, email@example.com Lars Norrby, IR, +46 (0)76-777 38 00, firstname.lastname@example.org Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se. Klö
Eurocastle Investment Limited - Change of Home State Regulator15.1.2021 13:00:00 CET | Press release
Contact: Oak Fund Services (Guernsey) Limited Company Administrator Attn: Mark Woodall Tel: +44 1481 723450 Change of Home State Regulator Guernsey, 15 January 2021 - Eurocastle Investment Limited has applied to change its home state regulator from the United Kingdom (“UK”) FCA to the Netherlands AFM as a result of the UK having left the European Union as at 31 December 2020. ADDITIONAL INFORMATION For investment portfolio information, please refer to the Company’s most recent Financial Report, which is available on the Company’s website (www.eurocastleinv.com). ABOUT EUROCASTLE Eurocastle Investment Limited (“Eurocastle” or the “Company”) is a publicly traded closed-ended investment company, focused on Italian performing and non-performing loans, Italian loan servicing platforms and other real estate related assets in Italy. On 18 November 2019, the Company announced a plan to realise the majority of its assets with the aim of accelerating the return of value to shareholders. The Comp
CrossAmerica Partners to Announce Year-End/Fourth Quarter 2020 Earnings Results on March 115.1.2021 12:45:00 CET | Press release
Allentown, Jan. 15, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce Year-End/Fourth Quarter 2020 Earnings Results on March 1 ALLENTOWN, PA, January 15, 2021 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its year-end/fourth quarter 2020 results after the market closes on Monday, March 1, 2021. In conjunction with the news release, management will host a conference call on Tuesday, March 2, at 9:00 a.m. Eastern Time. The conference call numbers are 800-774-6070 or 630-691-2753 and the passcode for both is 7265208#. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor section of the CrossAmerica website (www.crossamericapartners.com). To listen to the audio webcast, go to https://caplp.gcs-web.com/webcasts-presentations https://caplp.gcs-web.com/w
Negotiations concerning an acquisition of ThyssenKrupp’s mining business15.1.2021 12:30:16 CET | Press release
Company Announcement No. 1-2021, 15 January 2021 FLSmidth today announces that it is in negotiations with ThyssenKrupp concerning an acquisition of ThyssenKrupp's mining business. The negotiations are at a non-binding stage. Accordingly, there can be no assurances as to whether and when a transaction will transpire. Any transaction, if entered into, would be subject to, amongst other, statutory clearances from authorities, including approvals from merger control authorities. Contacts Media Relations Rasmus Windfeld, +45 40 44 60 60, email@example.com Investor Relations Nicolai Mauritzen, +45 30 93 18 51, firstname.lastname@example.org About FLSmidth FLSmidth provides sustainable productivity to the global mining and cement industries. We deliver market-leading engineering, equipment and service solutions that enable our customers to improve performance, drive down costs and reduce environmental impact. Our operations span the globe and our close to 11,000 employees are present in more than 60 count
RESULT OF SEK TENDER OPERATION FOR ONWARD LENDING15.1.2021 11:30:00 CET | Press release
AuctionAuction resultsAuction date2021-01-15Settlement date2021-01-19Final repayment date2025-01-20Offered volume, SEK bn50Total bid amount, SEK bn0Number of bids0Alloted volume, SEK bn0Interest rateRepo rateAdditional interest rate, %0.10
Correction: Correction: RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS15.1.2021 10:22:14 CET | Press release
Auction date2021-01-15Loan1053Coupon3.50 %ISIN-codeSE0002829192Maturity2039-03-30Tendered volume, SEK mln1,000 +/- 500Volume offered, SEK mln3,500Volume bought, SEK mln958Number of bids16Number of accepted bids5Average yield0.314Lowest accepted yield0.306Highest yield0.318% accepted at lowest yield 43.20 Auction date2021-01-15Loan1063Coupon0.50 %ISIN-codeSE0015193313Maturity2045-11-24Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,750Volume bought, SEK mln500Number of bids20Number of accepted bids6Average yield0.472Lowest accepted yield0.467Highest yield0.476% accepted at lowest yield 33.33